Un estudio para investigar los cambios en los síntomas en participantes adultos con rinosinusitis crónica con poliposis nasal que inician tratamiento con tezepelumab (ESSENCE)
Un estudio multicéntrico de fase 3b, de un solo brazo, para evaluar los cambios en los síntomas en participantes adultos con rinosinusitis crónica con poliposis nasal que inician el tratamiento con tezepelumab (ESSENCE)
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma.
Study details include:
- The study duration will be up to 40 weeks.
- The treatment duration will be up to 24 weeks.
- The visit frequency will be once every 4 weeks (Q4W).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a multicentre, open-label, single-arm, phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.
Approximately 60 sites in 10 countries will enrol adult patients with physician determined surgery eligible CRSwNP.
The study is divided into 3 periods as described below:
- Screening Period (from Week -4 until Week 0, up to 4 Weeks)
- Treatment period (Week 0 to Week 24)
- Safety Follow-up Period (Week 24 to Week 36)
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Marburg, Alemania, 35043
- Research Site
-
Tübingen, Alemania, 72076
- Research Site
-
Villingen-Schwenningen, Alemania, 78052
- Research Site
-
Wiesbaden, Alemania, 65183
- Research Site
-
-
-
-
-
Plovdiv, Bulgaria, 4003
- Research Site
-
Sofia, Bulgaria, 1431
- Research Site
-
Sofia, Bulgaria, 1606
- Research Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8S 1G5
- Research Site
-
-
Quebec
-
Québec, Quebec, Canadá, G1V 4W2
- Research Site
-
Québec, Quebec, Canadá, G1L 3L5
- Research Site
-
-
-
-
-
Barcelona, España, 08035
- Research Site
-
Barcelona, España, 08003
- Research Site
-
Cadiz, España, 11011
- Research Site
-
Madrid, España, 28041
- Research Site
-
Salamanca, España, 37007
- Research Site
-
Santiago de Compostela, España, 15706
- Research Site
-
-
-
-
California
-
Newport Beach, California, Estados Unidos, 92663
- Research Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Research Site
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, Estados Unidos, 02467
- Research Site
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65201
- Research Site
-
-
-
-
-
Le Kremlin-Bicêtre, Francia, 94270
- Research Site
-
Marseille, Francia, 13005
- Research Site
-
Nantes, Francia, 44093
- Research Site
-
Pierre-Bénite, Francia, 69495
- Research Site
-
Poitiers, Francia, 86000
- Research Site
-
Toulouse, Francia, 31400
- Research Site
-
-
-
-
-
Budapest, Hungría, 1085
- Research Site
-
Budapest, Hungría, 1134
- Research Site
-
Nyíregyháza, Hungría, 4400
- Research Site
-
Pécs, Hungría, 7621
- Research Site
-
-
-
-
-
Bologna, Italia, 40139
- Research Site
-
Catania, Italia, 95123
- Research Site
-
Florence, Italia, 50139
- Research Site
-
Padua, Italia, 35128
- Research Site
-
Pisa, Italia, 56126
- Research Site
-
Roma, Italia, 00168
- Research Site
-
Rozzano, Italia, 20089
- Research Site
-
-
-
-
-
Bialystok, Polonia, 15-879
- Research Site
-
Bydgoszcz, Polonia, 85-231
- Research Site
-
Lodz, Polonia, 90-302
- Research Site
-
Zawadzkie, Polonia, 47-120
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participants must be 18 years of age or older, at the time of signing the informed consent.
- Participants with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 who have all of the following:
- Severity consistent with the need for surgery as defined by total NPS ≥ 4 (at least 2 for each nostril) at screening, as determined by the central reader
- Mean NCS ≥ 2 in the 2 weeks prior to Visit 2
- Ongoing documented NP symptoms for > 8 weeks prior to screening such as rhinorrhoea, reduction or loss of smell and/or poor quality/loss of sleep
- SNOT-22 total score ≥ 30 as assessed at screening. Note: approximately 50 participants with a NPS = 4 at screening will receive treatment with tezepelumab.
- Any standard of care for treatment of CRSwNP, which must include treatment with intranasal corticosteroids, provided the participant is stable on that treatment for at least 30 days prior to Visit 1. Investigators should also assure that participants are compliant and on a stable dose of the background INCS during study period.
- Either 1) documented treatment of NP exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or contraindications/intolerance to) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 OR 2) any history of NP surgery (or contraindications/intolerance to)
- Body weight of ≥ 40 kg at Visit 1
- Female participants:
- Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of non childbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.
- Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the first IMP administration without an alternative medical cause.
The following age-specific requirements apply:
- Women < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range.
- Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
- WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:
- Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
- Intrauterine device
- Intrauterine hormone-releasing system
- Bilateral tubal occlusion
- Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP participant and that the vasectomised partner has received medical assessment of the surgical success)
- Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
- Cessation of contraception after this point should be discussed with a responsible physician.
- Provision of signed and dated written ICF as described in Appendix A 3 prior to any mandatory study-specific procedures, sampling, and analyses.
- Participant who is capable of giving signed informed consent as described in Appendix A 3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
Participants with documented allergic fungal rhinosinusitis and/or central compartment atopic disease.
-
Any clinically important pulmonary disease other than asthma (eg, active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc) that could confound interpretation of clinical CRSwNP endpoints results.
-
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
- Affect the safety of the participant throughout the study
- Influence the findings of the study or the interpretation
- Impede the participant's ability to complete the entire duration of study.
-
Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
-
Participants with conditions or concomitant disease that makes them non-evaluable for the primary CRSwNP endpoints such as:
-
Antrochoanal polyps
-
Nasal septal deviation that occludes at least one nostril
-
Acute sinusitis, nasal infection, asthma exacerbation or upper respiratory infection at screening or in the two weeks before screening, or Churg-Strauss syndrome (also known as eosinophilic granulomatosis with polyangiitis), Young's syndrome or Kartagener's syndrome
-
History of cancer:
- Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1.
- Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.
-
Uncontrolled epistaxis within 2 months of Visit 1
-
A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
-
For participants with comorbid asthma: Current smokers or participants with a smoking history ≥ 10 packs per year and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack per year and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
-
History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
-
Tuberculosis requiring treatment within the 12 months prior to Visit 1.
-
Major surgery within 8 weeks prior to Visit 1 or planned NP surgery or planned surgical procedures requiring general anaesthesia or inpatient status for more than 1 day during the conduct of the study.
-
History of known immunodeficiency disorder including a positive HIV test at Visit 1, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
-
Infection requiring systemic antibiotics within 14 days prior to Visit 1. Note: Participants with respiratory infections requiring antibiotics within 14 days prior to Visit 1 may extend their screening period to allow recovery and return no sooner than 14 days after completion of therapy.
-
Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae (eg, participants who have long-term post-COVID-19 anosmia).
-
Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1.
-
Treatment with systemic immunosuppressive/immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for SCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
-
Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Tezepelumab
Tezepelumab: Tezepelumab single dose subcutaneously injection. |
IMP. Subcutaneous injection. Unit dose strengths 210 mg.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in nasal congestion
Periodo de tiempo: Week 24
|
Changes from baseline in participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) as part of the nasal polyposis symptom diary (NPSD) following initiation of tezepelumab treatment. |
Week 24
|
|
Change from baseline in sino-nasal symptoms
Periodo de tiempo: Week 24
|
changes from baseline in participant reported sino nasal symptoms as evaluated by sino nasal outcome test, 22 item (SNOT 22) total score following initiation of tezepelumab treatment. |
Week 24
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of NCS responders
Periodo de tiempo: End of treatment - Week 24
|
Proportion of NCS responders (minimal clinically important difference [MCID] from baseline = 1.0) at each collected timepoint. |
End of treatment - Week 24
|
|
Time to first response for NCS
Periodo de tiempo: End of Treatment-week 24
|
Description of time to first response for NCS by analysing data at all collected timepoints. |
End of Treatment-week 24
|
|
Change from baseline in NCS
Periodo de tiempo: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24).
|
Change from baseline in NCS at each collected timepoint. |
Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24).
|
|
Proportion of SNOT-22 responders
Periodo de tiempo: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
Proportion of SNOT-22 responders (MCID from baseline = -8.9) at each collected timepoint. |
Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
|
Time to first response for SNOT-22
Periodo de tiempo: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
Description of time to first response for SNOT-22 by analysing data at all collected timepoints. |
Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
|
Change from baseline in SNOT-22
Periodo de tiempo: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
Change from baseline in SNOT-22 at each collected timepoint. |
Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
|
|
Change from baseline visit in nasal blockage (NB)
Periodo de tiempo: Weeks 0, 4, 12, and 24.
|
Change from baseline visit in NB measured by PNIF |
Weeks 0, 4, 12, and 24.
|
|
Change from baseline visit in NB
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
Change from baseline visit in NB measured by VAS-NB |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
|
Proportion of PNIF responders
Periodo de tiempo: Weeks 0, 4, 12, and 24.
|
Proportion of PNIF responders (MCID from baseline =20 L/min). |
Weeks 0, 4, 12, and 24.
|
|
Proportion of VAS-NB responders
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
Proportion of VAS-NB responders (MCID from baseline = -3.0) (in participants with VAS-NB ≥ 7 at baseline). |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
|
Time to first response for PNIF
Periodo de tiempo: Weeks 0, 4, 12, and 24
|
Description of time to first response for PNIF by analysing data at all collected timepoints. |
Weeks 0, 4, 12, and 24
|
|
First response for VAS NB
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
Description of time to first response for VAS NB by analysing data at all collected timepoints (in participants with VAS-NB ≥ 7 at baseline). |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
|
|
Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks
Periodo de tiempo: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks |
Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
|
Change from baseline in loss of smell score evaluated by VAS-Taste
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Change from baseline in loss of smell score evaluated by VAS-Taste |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Change from baseline in loss of smell score evaluated by VAS-Smell
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Change from baseline in loss of smell score evaluated by VAS-Smell |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Proportion of UPSIT responders
Periodo de tiempo: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24.
|
Proportion of UPSIT responders (MCID from baseline = 4) |
Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24.
|
|
Proportion of Sniffin sticks responders
Periodo de tiempo: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
Proportion of Sniffin sticks responders (MCID from baseline = 6) |
Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
|
Proportion of VAS-Smell responders
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Proportion of VAS-Smell responders (MCID from baseline = -3.0) (in participants with VAS-Smell ≥ 7 at baseline) |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Proportion of participants with a reduction in VAS-Taste score from baseline
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Proportion of participants with a reduction in VAS-Taste score from baseline (in participants with VAS-Taste ≥ 7 at baseline) |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Time to first response for UPSIT/Sniffin sticks
Periodo de tiempo: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
Time to first response for UPSIT/Sniffin sticks by analysing data at all collected timepoints. |
Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
|
|
Time to first response for VAS Smell
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Time to first response for VAS Smell by analysing data at all collected timepoints (in participants with VAS-Smell ≥ 7 at baseline). |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Time to first improvement in VAS-Taste
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Time to first improvement in VAS-Taste by analysing data at all collected timepoints (in participants with VAS-Taste ≥ 7 at baseline). |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Change from baseline in sleep as evaluated by PSQI total score
Periodo de tiempo: Weeks 0, 12, and 24.
|
Change from baseline in sleep as evaluated by PSQI total score |
Weeks 0, 12, and 24.
|
|
Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score
Periodo de tiempo: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
|
Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score |
Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
|
|
Change from baseline in sleep as evaluated by VAS-Sleep
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Change from baseline in sleep as evaluated by VAS-Sleep |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Proportion of PSQI responders
Periodo de tiempo: Weeks 0, 12, and 24
|
Proportion of PSQI responders (MCID from baseline = - 4.4) |
Weeks 0, 12, and 24
|
|
Proportion of SNOT-22 Sleep domain responders
Periodo de tiempo: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
|
Proportion of SNOT-22 Sleep domain responders (MCID from baseline = -2.9) |
Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
|
|
Proportion of participants with any improvement in VAS Sleep from baseline
Periodo de tiempo: Daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Proportion of participants with any improvement in VAS Sleep from baseline (in participants with VAS-Sleep ≥ 7 at baseline) |
Daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Time to first response for PSQI
Periodo de tiempo: Weeks 0, 12, and 24.
|
Time to first response for PSQI by analysing data at all collected timepoints. |
Weeks 0, 12, and 24.
|
|
Time to first response for SNOT-22 Sleep domain
Periodo de tiempo: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24.
|
Time to first response for SNOT-22 Sleep domain by analysing data at all collected timepoints. |
Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24.
|
|
Time to first improvement for VAS-Sleep
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
Time to first improvement for VAS-Sleep by analysing data at all collected timepoints (in participants with VAS-Sleep ≥ 7 at baseline). |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
|
|
Change from baseline in total NPS
Periodo de tiempo: Screening, Weeks 2 and 24
|
Change from baseline in total NPS evaluated by nasal endoscopy. |
Screening, Weeks 2 and 24
|
|
Proportion of NPS responders
Periodo de tiempo: Screening, Weeks 2 and 24
|
Proportion of NPS responders (MCID from baseline = 1.0) at Weeks 2 and 24. |
Screening, Weeks 2 and 24
|
|
Change from baseline in NPQ score
Periodo de tiempo: Weeks 0, 8, 12, and 24.
|
Change from baseline in NPQ score |
Weeks 0, 8, 12, and 24.
|
|
Proportion of NPQ responders
Periodo de tiempo: Weeks 0, 8, 12, and 24
|
Proportion of NPQ responders (MCID from baseline = 7.0) |
Weeks 0, 8, 12, and 24
|
|
Time to first response for NPQ
Periodo de tiempo: Weeks 0, 8, 12, and 24.
|
Time to first response for NPQ by analysing data collected at each specified timepoint. |
Weeks 0, 8, 12, and 24.
|
|
Change from baseline in TSS
Periodo de tiempo: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
Change from baseline in TSS |
daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
|
Proportion of TSS responders
Periodo de tiempo: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
Proportion of TSS responders (MCID from baseline = 4.0) |
daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
|
Time to first response for TSS
Periodo de tiempo: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
Time to first response for TSS by analysing data at all collected timepoints. |
daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
|
|
Change from baseline in NP severity
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Change from baseline in NP severity as measured by VAS Overall symptoms |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Proportion of VAS Overall symptom responders
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Proportion of VAS Overall symptom responders (MCID from baseline = 2.5) |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Time to first response for VAS-Overall symptom
Periodo de tiempo: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
Time to first response for VAS-Overall symptom by analysing data at all collected timepoints |
daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
|
|
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question
Periodo de tiempo: Weeks 0, 4, 8, 12, 20, and 24.
|
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question |
Weeks 0, 4, 8, 12, 20, and 24.
|
|
Time to first response for NP control
Periodo de tiempo: Weeks 0, 4, 8, 12, 20, and 24.
|
Time to first response for NP control by analysing data at all collected timepoints. |
Weeks 0, 4, 8, 12, 20, and 24.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization
Periodo de tiempo: Screening, Weeks 2 and 24
|
Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization from baseline to Week 24. |
Screening, Weeks 2 and 24
|
|
Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds [eg, Alternaria]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only)
Periodo de tiempo: Screening (for BEC and FeNO), Week 0 (for IgE and S. aureus enterotoxin IgE), Weeks 12 and 24
|
Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds [eg, Alternaria]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only) |
Screening (for BEC and FeNO), Week 0 (for IgE and S. aureus enterotoxin IgE), Weeks 12 and 24
|
|
Change from baseline in WPAI-CRSwNP
Periodo de tiempo: Week 0 and Week 24
|
Change from baseline in WPAI-CRSwNP |
Week 0 and Week 24
|
|
Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre-and post index (index = 1st tezepelumab dosing).
|
Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related). |
24 weeks pre-and post index (index = 1st tezepelumab dosing).
|
|
Change in incident rate of nasal infection comparing the post-index period versus the pre-index period
Periodo de tiempo: 24 weeks pre- and post-index. (index = 1st tezepelumab dosing)
|
Change in incident rate of nasal infection comparing the post-index period versus the pre-index period (index = 1st tezepelumab dosing). |
24 weeks pre- and post-index. (index = 1st tezepelumab dosing)
|
|
Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose)
Periodo de tiempo: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose) |
24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
|
Change in average SCS daily dose during the post-index period versus dose at/closest to the index
Periodo de tiempo: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
Change in average SCS daily dose during the post-index period (24 weeks following tezepelumab first dose) versus dose at/closest to the index |
24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
|
Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation.
Periodo de tiempo: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation. |
24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
|
|
Proportion of patients with CRSwNP exacerbation
Periodo de tiempo: 24-weeks pre- and post-index (index = 1st tezepelumab dosing).
|
Proportion of patients with CRSwNP exacerbation |
24-weeks pre- and post-index (index = 1st tezepelumab dosing).
|
|
Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score
Periodo de tiempo: Weeks 0 and 24.
|
Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score |
Weeks 0 and 24.
|
|
ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above
Periodo de tiempo: Weeks 0 and 24
|
ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above |
Weeks 0 and 24
|
|
Annualised asthma exacerbation rate
Periodo de tiempo: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
Annualised asthma exacerbation rate |
24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
|
Change from baseline in Annualised asthma exacerbation rate
Periodo de tiempo: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
Change from baseline in Annualised asthma exacerbation rate |
24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
|
Lung function (Forced expiratory volume in 1 second [FEV1]) (if available at site)
Periodo de tiempo: Weeks 0, 12 (lung function only) and 24.
|
Lung function (Forced expiratory volume in 1 second [FEV1]) (if available at site) |
Weeks 0, 12 (lung function only) and 24.
|
|
Asthma-related SCS use (yes/no)
Periodo de tiempo: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
Asthma-related SCS use (yes/no) |
24 weeks pre-and post-index (index = 1st tezepelumab dosing).
|
|
Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre-and post index (index=1st tezepelumab dosing)
|
Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related). |
24 weeks pre-and post index (index=1st tezepelumab dosing)
|
|
Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre and post index (index=ist tezepelumab dosing)
|
Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related). |
24 weeks pre and post index (index=ist tezepelumab dosing)
|
|
Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre- and post index (index=1st tezepelumab dosing)
|
Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related). |
24 weeks pre- and post index (index=1st tezepelumab dosing)
|
|
Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre-and post index (index=1st tezepelumab dosing)
|
Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related). |
24 weeks pre-and post index (index=1st tezepelumab dosing)
|
|
Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related).
Periodo de tiempo: 24 weeks pre-and post index(index=1st tezepelumab dosing)
|
Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related). |
24 weeks pre-and post index(index=1st tezepelumab dosing)
|
|
Asthma related SCS use as part of an exacerbation
Periodo de tiempo: 24 weeks pre-and post index(index=1st tezepelumab dosing)
|
Asthma related SCS use as part of an exacerbation |
24 weeks pre-and post index(index=1st tezepelumab dosing)
|
|
Asthma related SCS duration of use
Periodo de tiempo: 24 weeks pre-and post index(index=1st tezepelumab dosing)
|
Asthma related SCS duration of use |
24 weeks pre-and post index(index=1st tezepelumab dosing)
|
|
Asthma related SCS daily dose
Periodo de tiempo: 24 weeks pre-and post index(index=1st tezepelumab dosing)
|
Asthma related SCS daily dose |
24 weeks pre-and post index(index=1st tezepelumab dosing)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Tanya M Laidlaw, MD, Director of Translational Research in Allergy and Director of the Aspirin-Exacerbated Respiratory Disease (AERD) Centre at the Brigham and Women's Hospital.
- Investigador principal: Enrico Heffler, MD, PhD, Associate Professor of Internal Medicine and Consultant at the Personalized Medicine, Asthma and Allergy Unit at IRCCS Humanitas Research Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- D5242C00002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .